Brian Schultz, MD, PhD

Personal Statement

​I am interested in general psychiatry as well as consultation-liasion psychiatry, and pscyho-oncology.  I see patients in hospital and clinic settings, to address a broad range of illness including mood disorders, anxiety disorders, psychotic disorders, and coping and adjustment to medical problems including cancer.  I also enjoy and am involved in teaching and educating medical students and residents at various stages of training.


Psychiatry , Northwestern McGaw Medical Center , 2011-2015
Ph.D. , Molecular and Cellular Biology , UW Graduate School , 2009
MD , UW School of Medicine , 2011

Recent Publications

Off-target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
(2020 Nov 23)
Antimicrob Agents Chemother
Xu Y, Barauskas O, Kim C, Babusis D, Murakami E, Kornyeyev D, Lee G, Stepan G, Perron M, Bannister R, Schultz BE, Sakowicz R, Porter D, Cihlar T, Feng JY

Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation.
(2020 Mar 12)
ACS Med Chem Lett 11(3): 358-364
Farand J, Kropf JE, Blomgren P, Xu J, Schmitt AC, Newby ZE, Wang T, Murakami E, Barauskas O, Sudhamsu J, Feng JY, Niedziela-Majka A, Schultz BE, Schwartz K, Viatchenko-Karpinski S, Kornyeyev D, Kashishian A, Fan P, Chen X, Lansdon EB, Ports MO, Currie KS, Watkins WJ, Notte GT

Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
(2020 Apr)
Biochim Biophys Acta Gen Subj 1864(4): 129531
Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, Brendza KM, Lutz JD, Keegan KS, Ray AS, Schultz BE, Sakowicz R, Feng JY

Elucidating the Crystallite Size Dependence of the Thermochromic Properties of Nanocomposite VO2 Thin Films.
(2018 Oct 31)
ACS Omega 3(10): 14280-14293
Fleer NA, Pelcher KE, Nieto K, Braham EJ, Zou J, Horrocks GA, Naoi Y, Depner SW, Schultz BJ, Amano J, Sellers DG, Banerjee S

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®.
(2019 Aug 15)
Bioorg Med Chem Lett 29(16): 2428-2436
Taylor JG, Zipfel S, Ramey K, Vivian R, Schrier A, Karki KK, Katana A, Kato D, Kobayashi T, Martinez R, Sangi M, Siegel D, Tran CV, Yang ZY, Zablocki J, Yang CY, Wang Y, Wang K, Chan K, Barauskas O, Cheng G, Jin D, Schultz BE, Appleby T, Villaseñor AG, Link JO

Show complete publication list »